Neuromics is a multi-million pound European Union funded project which aims to revolutionize diagnostics and develop new treatments for ten major rare neuromuscular and neurodegenerative diseases.
It will do this by bringing together leading research groups in Europe, five highly innovative small and medium sized enterprises (SMEs) and overseas experts. Together, they will use the most sophisticated Omics technologies in order to:
- increase the number of patients with a genetic diagnosis;
- develop biomarkers for clinical application;
- improve understanding of pathophysiology and identify drug targets;
- identify disease modifiers;
- develop targeted therapies;
- translate findings to other, related disease groups.
Role of the UCL HD Research Team within Neuromics:
Professor Tabrizi is the disease coordinator for Huntington’s disease. She also leads Neuromics Work Package 3 which aims to identify disease modifying factors in cohorts enriched by deep phenotyping, including HD. This project links in with our group’s existing work on identifying genetic modifiers of HD.
The UCL HD team is also involved in Work Package 4 which aims to identify disease progression biomarkers in Huntington’s disease (HD), fronto-temporal lobe dementia (FTLD), Spinocerebellar ataxia (SCA), Hereditary Spastic Paraplegia (HSP).
This study involves some of the clinical data and blood samples collected as part of TRACK-HD. We are not recruiting subjects separately for this study.
Latest news- April 2014
The Neuromics project has now been underway for just over a year and has already made lots of good progress. Issue two of the Neuromics newsletter is now available which provides an update of all the recent work on this project, click here to read the newsletter.